<SEC-DOCUMENT>0001193125-11-347300.txt : 20111220
<SEC-HEADER>0001193125-11-347300.hdr.sgml : 20111220
<ACCEPTANCE-DATETIME>20111220163433
ACCESSION NUMBER:		0001193125-11-347300
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20111220
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20111220
DATE AS OF CHANGE:		20111220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		111272383

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d272651d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): December&nbsp;20, 2011 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>REPLIGEN CORPORATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-14656</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-2729386</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(781) 250-0111 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Completion of Acquisition or Disposition of Assets. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;20, 2011, Repligen Corporation, a Delaware corporation (&#147;Repligen&#148; or the &#147;Company&#148;), completed its acquisition of the Novozymes Biopharma Business (as defined below),
pursuant to the terms of the Asset Transfer Agreement (the &#147;Asset Transfer Agreement&#148;), dated as of October&nbsp;27, 2011, by and among the Company, Repligen Sweden AB, a company organized under the laws of Sweden and a wholly-owned
subsidiary of the Company (the &#147;Buyer&#148;), Novozymes Biopharma DK A/S, a company organized under the laws of Denmark (&#147;Novozymes Denmark&#148;), and Novozymes Biopharma Sweden AB, a company organized under the laws of Sweden and a
wholly-owned subsidiary of Novozymes Denmark (&#147;Novozymes Sweden&#148; and, together with Novozymes Denmark, &#147;Novozymes&#148;). Repligen acquired Novozymes&#146; business headquartered at Novozymes Sweden&#146;s facility in Lund, Sweden and
all related operations, including the manufacture and supply of cell culture ingredients and Protein A affinity ligands for use in industrial cell culture, stem and therapeutic cell culture and biopharmaceutical manufacturing, and the provision of
contract manufacturing services for ALK Abello A/S (the &#147;Novozymes Biopharma Business&#148;). Pursuant to the Asset Transfer Agreement, the Buyer (a)&nbsp;purchased all of the assets related to the Novozymes Biopharma Business and assumed
certain specified liabilities related to the Novozymes Biopharma Business from Novozymes Sweden and (b)&nbsp;purchased contract rights and licenses used in the Novozymes Biopharma Business and other specified assets from Novozymes Denmark
(collectively, the &#147;Transferred Business&#148; and the acquisition of the Transferred Business, the &#147;Transaction&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the
consummation of the Transaction, the Company paid a purchase price of 17.0&nbsp;million Euros (~$22.7 million) to Novozymes. In addition, Novozymes has the right to contingent payments of up to 4.0&nbsp;million Euros (~$5.2 million) consisting of:
(i)&nbsp;an earn-out of 1.0&nbsp;million Euros (~$1.3 million) if the Transferred Business achieves sales of a minimum quantity of a Novozymes product between January&nbsp;1, 2012 and December&nbsp;31, 2012; (ii)&nbsp;two milestone payments of
1.0&nbsp;million Euros (~$1.3 million) each if sales of certain Novozymes products achieve agreed levels for the combined calendar years 2012 and 2013 and for calendar year 2014, respectively; and (iii)&nbsp;technology transfer payments totaling
1.0&nbsp;million Euros (~$1.3 million) following the successful transfer of certain Novozymes manufacturing technology. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing
description of the Transaction and the Asset Transfer Agreement does not purport to be complete and is qualified in its entirety by reference to the Asset Transfer Agreement, which was filed as Exhibit 2.1 to the Company&#146;s Form 8-K filed on
October&nbsp;28, 2011, and is incorporated herein by reference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Asset Transfer Agreement has been included to provide investors and
securityholders with information regarding its terms. It is not intended to provide any other factual information about the Company or Novozymes. The Asset Transfer Agreement contains warranties and covenants that the Company and the Buyer, on one
hand, and Novozymes, on the other hand, made to each other as of specific dates. The assertions embodied in those warranties and covenants were made solely for purposes of the Asset Transfer Agreement between the parties and may be subject to
important qualifications and limitations agreed to by the parties in connection with negotiating its terms, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Asset Transfer
Agreement. Moreover, the warranties may be subject to a contractual standard of materiality that may be different from what may be viewed as material to investors or securityholders, or may have been used for the purpose of allocating risk between
the parties to the Asset Transfer Agreement rather than establishing matters as facts. Moreover, information concerning the subject matter of the warranties may change after the date of the Asset Transfer Agreement, which subsequent information may
or may not be fully reflected in the Company&#146;s public disclosures. For the foregoing reasons, no person should rely on the warranties as statements of factual information at the time they were made or otherwise. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;7.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Regulation FD Disclosure. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
December&nbsp;20, 2011, the Company issued a press release announcing the closing of the Transaction. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information provided in this Item&nbsp;7.01 and the exhibits attached hereto shall not be deemed &#147;filed&#148; for purposes of
Section&nbsp;18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)
<I>Financial statements of business acquired.</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The historical combined financial statements of the Transferred Business required by
Item&nbsp;9.01(a) of Form 8-K will be filed by amendment within 71 calendar days after the date this report on Form 8-K must be filed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)
<I>Pro forma financial information.</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pro forma financial statements required by Item&nbsp;9.01(b) of Form 8-K will be filed by
amendment within 71 calendar days after the date this report on Form 8-K must be filed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <I>Exhibits.</I> </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:23pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit<BR>No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset Transfer Agreement by and among Repligen Corporation, Repligen Sweden AB, Novozymes Biopharma DK A/S and Novozymes Biopharma Sweden AB, dated October&nbsp;27, 2011
(incorporated herein by reference to the Company&#146;s Form 8-K filed on October 28, 2011).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release by Repligen Corporation, dated December 20, 2011.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPLIGEN CORPORATION</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: December&nbsp;20, 2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Walter C. Herlihy</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Walter C. Herlihy</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;President and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:23pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit<BR>No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Asset Transfer Agreement by and among Repligen Corporation, Repligen Sweden AB, Novozymes Biopharma DK A/S and Novozymes Biopharma Sweden AB, dated October&nbsp;27, 2011
(incorporated herein by reference to the Company&#146;s Form 8-K filed on October 28, 2011).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release by Repligen Corporation, dated December 20, 2011.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d272651dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="middle">


<IMG SRC="g272651ex991logo.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen Corporation</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 Seyon
Street</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building #1, Suite 100</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Waltham, Massachusetts 02453</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telephone:
781-250-0111</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Telefax: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;781-250-0115</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONTACT: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura L. Whitehouse
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">VP, Market Development </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(781)
419-1812 </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Repligen Completes Acquisition of Novozymes Biopharma Sweden AB </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WALTHAM, MA &#150; December&nbsp;20, 2011</B> &#150; Repligen Corporation (NASDAQ: RGEN) announced today that it has completed the acquisition of the
business of Novozymes Biopharma Sweden AB, the Swedish unit of Novozymes Biopharma, a company focused on the manufacture and supply of growth factors used in mammalian cell culture and Protein A affinity ligands used in the production of monoclonal
antibodies. This transformative acquisition, which was first announced on October&nbsp;27, 2011, elevates Repligen to a world-leading supplier of products for manufacturing biologic drugs and provides the path to sustainable growth and
profitability. The combined company is expected to generate total revenue of approximately $50 million in calendar year 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are
very pleased to have achieved our goal of creating a path to sustainable profitability for the Company through the acquisition of the business of Novozymes Biopharma Sweden AB,&#148; stated Walter C. Herlihy, President and Chief Executive Officer of
Repligen Corporation. &#147;We look forward to quickly integrating our Swedish colleagues, leveraging the synergies within the combined organization and to continuing to supply premium products for the manufacture of biologic drugs.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Novozymes Biopharma Sweden AB acquisition diversifies and expands Repligen&#146;s product offering and customer base while doubling the
company&#146;s manufacturing capacity. The business is located in Lund, Sweden and operates a 45,000 sq. ft., c-GMP capable production facility which was recently renovated with an investment of ~$25 million. The products acquired in this
transaction are anticipated to generate $16-$17 million in revenue in 2011, and are sold primarily under long-term supply agreements with major life sciences companies including EMD Millipore, Sigma-Aldrich Corporation and GE Healthcare. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This was an all cash transaction in which Repligen made an upfront payment of 17&nbsp;million euros or $22.7 million. The transaction includes future
contingent milestone payments of 4&nbsp;million euros (~$5.2 million) payable in 2012-2015 based on the complete transfer of specific manufacturing technology and the achievement of specified revenue targets in 2012-2014 for the products used in
cell culture. The combined bioprocessing business is expected to generate $35-38&nbsp;million in product revenue in calendar year 2012 and will have low selling, general and administrative expenses since the majority of the revenue derives from
long-term supply agreements. In addition, we expect that the profit generated over the next several years will benefit from our $57 million in net operating loss Federal tax credits. At the end of our current fiscal year, ending December&nbsp;31,
2011, we expect to have $35-$37 million in cash and no debt. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For many years, Repligen has been a leader in the supply of four forms of
recombinant Protein A, a key ingredient used in the production of most monoclonal antibodies. Through this transaction, Repligen </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- more -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Completes
Acquisition of Novozymes Biopharma Sweden AB, December&nbsp;20, 2011 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Page 2 of 2 </I></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
has acquired &#147;native&#148; Protein A which is used in the production of several of the early blockbuster monoclonal antibody drugs. There are more than 50 approved monoclonal antibody
products and 200 candidates currently in clinical development, most of which are manufactured using Protein A. Repligen now sells more than twenty products to the biopharmaceutical industry under both long-term supply agreements with four leading
life sciences companies as well as directly to a variety of end-users. As part of the acquisition, GE Healthcare and Repligen have extended the term of their existing supply agreement for recombinant Protein A from 2014 to 2021. In addition,
Repligen has expanded into the cell culture ingredients market which increases our product breadth and opens a market opportunity in the production of fermentation ingredients as well as a future market opportunity as stem cell and cell-based
therapies emerge. The combined company is well positioned to fully benefit from the long-term growth of the monoclonal antibody market. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Biologic Drugs and the Biologics Market </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Biologics include a wide range of protein based drugs such as recombinant therapeutic proteins, monoclonal antibodies and vaccines. In 2010, five of the top ten selling drugs were biologics and it is
estimated that by 2014 eight of the top ten selling drugs will be biologics. The global biologics market in 2010 was approximately $150 billion of which $48 billion in revenue was derived from monoclonal antibody products. Growth of the biologics
market is expected to continue, as 40% of the new drugs in development are biologics, the highest proportion in history. By 2015, the global biologics market is expected to reach approximately $240 billion, an annual growth rate of ~10%, with
monoclonal antibody drugs growing at ~12% to approximately $86 billion. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Repligen Corporation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repligen Corporation is a leading supplier of critical biologic products and ingredients used to manufacture biologic drugs.&nbsp;Repligen also applies
its expertise in biologic product development to Secreflo&#153;, a hormone which is being developed as a novel imaging agent for the diagnosis of a variety of pancreatic diseases. In addition, we have two early stage CNS rare disease programs which
are advancing into Phase 1 clinical trials. Repligen&#146;s corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested at www.repligen.com. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section&nbsp;27A of the Securities Act
of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that express or implied
statements in this press release which are not strictly historical statements, including, without limitation, statements regarding the performance of the combined Repligen and Novozymes Biopharma Sweden AB business following the closing of the
Novozymes Biopharma Sweden AB acquisition, future financial performance and position, plans and objectives for future operations, and plans and objectives for product development, regulatory approval, and product sales constitute forward-looking
statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, the termination of customer contracts prior to
the end of their term; Repligen&#146;s inability to successfully integrate the bioprocessing business of Novozymes Biopharma DK A/S and Novozymes Biopharma Sweden AB and its employees into Repligen and achieve expected synergies; the Company&#146;s
ability to accurately forecast the acquisition, related restructuring costs and allocation of the purchase price, goodwill and other intangibles acquisition related and other asset adjustments; the impact of foreign currency fluctuations on its
operating results and profitability; costs associated with restructuring of certain European operations; costs associated with and consequential to the acquisition and integration of Novozymes&#146; bioprocessing business and benefits realized from
the acquisition; risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new
approaches to the treatment of our targeted diseases, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital, the success of our clinical trials, our ability to develop and
commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration and EMEA regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the
risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile
stock price, and other risks detailed in Repligen&#146;s filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the
announcements described herein except as required by law. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>### </I></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g272651ex991logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g272651ex991logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`(0"6`P$1``(1`0,1`?_$`'(```$%`0$!````````
M``````@`!@<)"@L$!0$!`````````````````````!````8"`0,"!0(#"0``
M`````@,$!08'`0@)`!$*$A,A(A05%E$R,4$74B2U-G:W&#AX$0$`````````
M````````````_]H`#`,!``(1`Q$`/P"U3RVMU[0U(X_:KCE&V=-JFM>\MAX^
MR)997DJ=H=+$D$@<9D,LEN$#XQ+$+LG(4/OV-.?@HT(3"E&0#[A%G&0SG:A<
M8_DL;J:W51M+5/(?-F2N+E8%,GAR"PMV-AH_+OLI+RYLR=8ZM#9'W]$D`YY:
MQ*4WH5F^XD-*'GTY%D(0$_:B_P#R#N"?9*MV>^=R+.D3O*F8BP(H0\W5(=A:
M.LZ.M+N-K>F9V8)\+W<92JB\IEI1J)M<B"E(#4QQ?N%']!U"-4KMSLKK!KKL
M2)B,BX[UH^J[>-C1HC#!1\ZQH.QRTYFP:<$!IX&PUVR2$P00B,"#`LXQW[=!
M&DFY%-`87-/Z<R[=W4N,3P*L:`V(/VP]3-4A2KRS/:$@6M2V6$JT*[!ORX).
M"`S(OA@/?H"];W!`[($3HU+4CDV.21.O;G%O4DK$"]"K*`H2+$2M.,Q.J2*B
M#`C+,`(0!@%C.,YQGOT$9L-\T;*GQVC$8N:J)')6%*Z+GR/,-B1!X?&9$QFA
M(>ECLTM[PH7MR5G.%@"HPXL`$XLXP9D.>@BVO]Z-*K9L(VI:NVYUHL:T"332
M,U[![QK253,P].$8E)":.,DE6NJLY)@L7O`**&(GMGUX#VZ",>4O8A5JAQT;
MH;!-CF<S2*NM>K'5PQT3J1)%*&P7UB416O%"92'YR%()P^M_MB#\V!]NWQ[=
M!F;\.ZQMJ=@X)NKL+LIL7>5T1QJDU95!7B6VK0F<Y9&%R:&=_FUA+FTB4O+B
MD0KC$,ACX##2PA'@KOC.>V>V0=/'=HKO',>;*?[K6YOI0]NZ]$V#L5;[/0%%
M[GR6V5#.TSK\FC%5,[Q4[:F2QANC,-22Y'D8A"RF(6(B0@P(0@]`=G+YS$W9
M35^5QQ@<8\!:[LY);P*0&J%+FF2.L)USBCPA.=$\GEJ988!G/E.8\28\8*<Q
M!:V9F+"XN`#BCDR92`:C\7K8#:!M(L3D9Y<]K+7OMU3E+UZ:L%8$%90AW%C)
MN&N+))8>J+6M+:=G&"Q(6F-EBQCY$Q..W0"#!K6Y#O'5Y+=2-/+_`-J9/N?Q
MZ[ER9NA4`=[$RY*I/!/NDM98.L7,P']XD;U"I!6+],&A6Y($3DL87AF7>HL@
ME:(.$0;SN@'Z0[9ZKQ&:`K>5[+Z_1BQ#%>$`(%(;EKEEF@UV1X+PB!%G*1IG
MP2O)F<!P7@CU]\]NW?H"`QG`L8$'.,XSC&<9QGOC.,_'&<9Q\,XSCH&*NM*L
M6N-/4S<[&@C=#XV,94BE:Z7Q])&F`PO!>3"WI]4.!;6U#!@X'?!YI><>O'ZX
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M:B:*PI$^6?5$*8G7S)!"D;K(#?=`%<B7)"33,)BE92@*U-B.('@\JG06Q)S6
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MEM5M:U,C1*DR@HX(LBR`LT0:4?(.W7F<H\;K2IUG2TTFU=[F+4-7/2@X^D-=
M`I:Q17K.7?)!6"<%(U<PC+8(16`X`'"T(>W;H)#XMPYX\/%$M[8<X(668V/3
M>SEZH5'Q3G?F-F*G*GZ94B.]/K%E:D:(V:7G]#L8Q^O0`SX9-=,55TYR2;VS
M-+D#%#66*UVB=<%`P8F8*[B\GN&U$Y"@6.^/>2*X\8(/[>Y(<Y_ACH##\32!
M.NT$[Y%N7:Z4^'VZ]@[]>:LCCXOQ]29%F+)#1:=@,\>/.P,Q,T*S99&FP@L&
M0A3(H^40#&"^X>@NZY0.7L_C<F]5P5JTEVBVV<+(BK[+5[A0447N[/"$;6[I
MV=N1O[B4QNJ;+F^'_4C+("((RBDWJ%CL8#/05A4SY&5)[?;HZPZ?V=Q5WQ"K
M=M6<M*"NG+8./08EP@;:Y*CE3Q8S4UR^-D2`AH9$D54+#CV_`!&Y;,A"/)A6
M/2'KYU]_K9G^W6O7"UJUL+'-5'Z^68,[V_VH>)<V0LZGJ14I'IPQ#F"3.;NP
MEM$DD47CZU>H+(6HUR_"AJ0$*"BW!2+`1!8/`AXY9VLTQKZ.7Y5Q=W8A;\I9
M=EWK=AF>;&,GY;*J-0RA]C8;$(K%T1*'H(3EC>6Q$E'%"&$O)1F0G!!P\#W(
M!9;+XY.Q%]6[+'*2.FD:+9^#U])GM<I<W5PCM<U;';"K5D-<E@A*5@6EZG!;
M&W8$(7M(DR8@/8)80X`$_'@X,H=NEH9$[MY`I+8]@ZY36T[!L6A=3&:;2.O:
MV>'K*U#!Y=?EKG0E?'Y3,YI)%T&"ULX35I8$#.VX,",T"[!9(13(^)'32OO)
M6@7&_4L2F'_"&]M93[%VBH1/:%AX:!)X_&I_:T6ACA*4LD)G0XB1;M6P-_*3
MJ7,TX!YV"PFX(&`L(!5L2$ODE\MA%"<B!(X6R;H5U7QZ(&`+&\ROM1F5H.L%
M$'&?=(&@<PU8]&F9S\@A*A9_GT'3AE4:K=+&)$KE42B2J,I&-U62%.Y1UH6M
MYS*E0GJ'0"U(H1F$*4HD18_<`,(@B#WQG&<=!R^?%;@9%W\Z2FWX>QD1J&59
M`MF;I(8VQ/A*UL,?FY"FK(]'4Q!8?;3)$']6R"R2L=L!`F[8_AVZ!@<K#93=
M<^3%<+IR,PV02#5R0W]`)%9*!.*5)3GJAY-6,7:HS(6A3$EC;)W!IC*#"89X
M&D_ZH8FM0E*P(X.2LA8IN?8GB`ZVQF)K*'U57[KS:4.I9!\,J&ZMI(HCC##]
M.>8:]R.6SN9(&TE68K"40G;4Q2E:8(S(C`DEAP(0';O7']>-#?&HON;:[:82
M/0!XY`7NL8NLI&<V3*[&L$@F;29(!.?+G26.CFO9G)]HV).:O[*')0FX"X1:
MDL"KZ@`0!WQ6.7?0/0C6O8VB-OK4(H69RBY`7-%I9(8E-'IBG,260.+1(3(A
M7Q".R,\AYC3G%E!P4Z@LK"HMQQ]-DT8#@@`->0^_YCY.7,#1U#Z?1V5$T#`6
MQ/6\1F#VS*D1K-6_Y(!^NS9"8M1^!YBS2<G-(*;T2H12E42WMJ<99;@L^E"!
M/^8W,6IFN#CIT!JQ.8&-T-K^H>6*)(1X/,)_.GIFJBO6@P`,!R-:A8*=R`C'
M;'R+.^,?/T%J?DN.+?HWP`:R:2,)X$2N4N>LFNQR%(+VLK(W1L&#-Y.Y#]`P
MY,+-E5>-?OY^;`S%OQ_=T!8>/'IJ>3X]2*KQC*CTCW6A.S<K<G`XH6,(A7$F
MD=3Q!X48P7DPTK\%CC0JQVP+N6+';].@K>\5[?*G=+8GLOQ4;J2Z-:S;%5KL
MK-)9&VVW7AN@S1)UC@QQF&S.$(Y&_*$+'F5QM]@>%2=.:>`QU0N99B+!X"3<
MA#5EM!RC\?\`IY7+O9EZ[64RP-3:@4*V^.,4YCTPL&6J"4YIY+5"X#&'!SE$
ME<EN2_0#!";)!>18$<845@1@0R"\2ETVIRP^2[;.[5MUA**JCNN.MCZ[5%6,
MZ0*4D@KF`29E9*^IYO=TBXDO*=^FD3MEXE9PB^Y`E3B<-*(:?VA]`W);1>D]
MS^5)O?5'+#'XRY5_9M51A3K>GM2:R.O(2]RM/!Z&Q`RVZ4L\FB81*%$"9WY$
MB),682GN1)R8(1*_:+R!Q<EFI?C(<;U68D#[IE5-X7M)7%F8JEU:JZ_;A<[;
MLU]>G1`WD@3MS3:$C6QIB3$K,G#<5:(1)HPA3)PGJSB2!AX^:%LJW03QOC:A
MI76--I,MW%L.H&1XUM2SIZLA[@<QL%Q;[8L".N\M>U"EP?9$5$ZJRUN7M?W8
M@W(B"O46$(AAJ"X^Z&*U>T;U(U\"EPC5U)KS4\-?"L!"')DI;8:T_ERLS`,8
M#[J^4&K#QY_CD9F<YSG/QZ#(YI?=J.9\[7,AR-NZD*R&4;=NH6@D6?E.<C:F
MQ-=>X5$ZEJU[<<('M@+*8*W7GC$']I3B,6<]C.^0TUT#PV\:^KVQ&=L:-UC9
MX5L,)7-'#-G&6%;\I=LN%B)G)'-'#[=,K!D,?PM?TKRJ`:;A'@80J!X+R#U=
M!9!(6!HE;`^1>0(PN+#)&=S8'MO&:>0!<T/"(]N<D8CTII"HD*I&I&#(RQ@,
M#@7<(L9[9Z"N+47ARXW]#K24W3J5K<EIJREL6=84X2)FM&ZWT#E%7I4W+G%D
M<V.861(HZXHSE[0E4!]](8(D].687D`PXST#RWDXL]#N1U`Q$;>Z^QFSGJ*(
MSVZ*3I,X2"%V+'&U0HRK.:FV=PIV8)(-D$K$(W[>H4'H,'&#,P3@P619`:M3
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MIA&C]DLO`Q8R$5W[Q#\=6T>QC)MG?FMC19&P,</A"ADG[M/;80_0BKA60NAI
M0(LQSQKA9R1H6)\&9),;ADJ19%[X3?6/U!(>Z7&_I9R'M]?M.Y%)([I;*M62
M)Q@:%PFED1%.PKI60T)GY4$%?3&)_<#ER=B2@QE7[_LA+S[?H]9GJ`G:DJBO
M:)J^OZ7J6,(X76-61!@@4!B:!0O5I([$XNVIVAC:25CJK7NBP*)`E`#)RD\]
M0=G&1F&#&(0LA7/O9PF\;7(U)R;!V;UZ;G6U"4*5L%;,#D,BK:PG!N0$B3H$
M<B>(@XMJ68%-Z?."TV7A.O&F*`$LH0"PX#T$+ZK>.;Q$ZC2]ML.!ZM-D\GK(
MK3KV*47C)Y);V6-<D&(U*O:8Q*UZF"HW)*=D)A*L+5]428`(BS`BQWZ"S>NM
M2M=:EO:\MF:\J]GC5Z[)EP\J[;%3N#^L=IV5`FO[-$RE:-S=UK,TE-3;C!?I
M;DR,)_I"([!@PA%@!SWQXG=">2E-'A;=4,T3Z31!$:V1.PV9YD,&L=@:CE(U
M@V9-,H>YLSLX,.%AIAP&Y<)6@+.-,,`2$PP8A!"NEW`YQ;:%3EOM2A-9FD=L
M,QOU#!9EFR246I+(PI]&2\+HD.:NKHS1%T"6(0<+&Q&D68"(0?=](LXR!E[9
M:)ZH;S-E;LNUE1(+?9ZDFI5B0!J=9--V%O9)F2GPD*>CDD/DT=(>QEI>Y>"7
M`*I-Z!C#[?88^X%OT%=4(XF^/JN*NNJF85KNW,5=[$V="[EN=G)GUKJE\YLV
MNYRR65"I6MDZ^=JY4W*H_.HZD<B24*U*D$>6+`RA`--`,+%>@70+H%T"Z#GA
M>87_`-Y=7/\`RPE_WAL7H.@I!O\`),/_`-+1_P#PE)T#IZ!=`N@70+H%T"Z!
*=`N@70+H%T'_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
